Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 1;11(1):e2019025. doi: 10.4084/MJHID.2019.025

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

The proportion (%) of Italian patients from SIMPLICITY with documented response monitoring. (A) CyR monitoring for the overall population, and for those patients receiving IM and second-generation TKIs, over the years of first-line TKI initiation. Both FISH and BM cytogenetic tests were included as long as a date was documented. Patients had to be followed for ≥12 months. Includes assessments performed after index TKI start date, between 30 days and 12 months later. (B) MR monitoring patterns during the first 12 months of treatment according to the year of first-line TKI initiation – result on IS. Dashed line corresponds to the proportion of patients with CyR or MR monitoring during the first 12 months across the entire study period. N indicates the number of patients per cohort. BM: bone marrow; CyR: cytogenetic response; FISH: fluorescence in situ hybridisation; IM: imatinib; IS: international scale; MR: molecular response TKI: tyrosine kinase inhibitor.